Trial

A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers

Study Director
Annelize Koch
Start Date
1 / 2019
Trial Phase
Phase I
Trial Status
enrolling
Current Enrollment
Target Enrollment
120
Overview

Randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD and MAD) trial conducted by Simbec Research Ltd., U.K.

Registry Link
Developer Associations
Spero Therapeutics, LLC
Compound Associations
SPR720 (Fobrepodacin)